NHS England will be the first health service in the world to routinely offer genomic medicine from 1 October 2018, enabling the analysis of patient DNA to help diagnose rare diseases, match patients to the most effective treatments, and reduce adverse drug reactions.

The move comes as the NHS celebrates its 70th birthday and represents an important step towards ‘precision medicine’ in the healthcare service, enabling more efficient therapies tailored to individual patients.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As reported in The Guardian, the service will see new cancer patients have their tumour DNA routinely screened for key mutations that could indicate the best treatment going forward, or to propose experimental therapies that could be suitable.

As well as aiming to provide patients with the most effective individualised treatments as quickly as possible, the service is expected to create a bank of data on the relationship between DNA, health and lifestyles. Such information could be used by researchers to learn more about cancer and other diseases.

Genomics England chief scientist Professor Mark Caulfield said: “We are ushering in a new era of genomic health. This is a big step and it grows over the new two years. It’s a total transformation.”

The genomic medicine service will initially launch in England but discussions of other countries in the UK becoming involved are underway.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The NHS service will build on foundations laid by Genomics England’s 100,000 Genomes Project. The state-owned company has set up seven genomic hubs across England to deliver DNA tests on cancer and rare diseases as well as many other conditions.

A separate lab in Cambridge will perform whole genome sequencing and 13 other national genomic medicine centres will draw on multidisciplinary teams of specialists to write reports for patients after deciphering the results of routine DNA testing. Details of the tests will be stored in a national directory that will be updated yearly as genetic medicine advances.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact